MedWatch

Food allergy venture to boost ALK's growth

In future years, allergy company ALK will go all-in on winning the billion-dollar (US) food allergy market, which in spite of a sparse customer base is many times the size of the respiratory allergy market in which ALK has previously placed stakes.

Photo: ALK / PR

Things are going well for Danish allergy company ALK, which develops and sells immunotherapies for allergies caused by triggers such as house dust mites, pollen and grass.

To ensure future growth, however, the product pipeline must be developed, for which reason the allergy company is venturing into the area of food allergies, which takes up a huge market globally – many times the size of the market for respiratory allergies, which ALK has been present in for some time.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs